



Biosign Technologies Earns Certified Partner Status In Microsoft Partner Program

TORONTO, ONTARIO, Monday, February 8, 2010 – Biosign Technologies Inc. (**CNSX: BIO**) (“Biosign” or the “Company”) today announced it has earned Certified Partner status in the Microsoft Partner Program, which recognizes Biosign’s expertise and impact in the technology marketplace. Microsoft Certified Partners receive a rich set of benefits, including access, training and support, giving them a competitive advantage in the marketplace.

“Only companies that have demonstrated high levels of customer service, proved their experience and attained advanced certification receive the designation of Microsoft Certified Partner,” said Allison Watson, corporate vice president of Worldwide Partner Group at Microsoft Corp. “Today, Microsoft recognizes Biosign for its skills and expertise in providing customer satisfaction with Microsoft products and technology”.

The Microsoft Partner Program was launched in October 2003 and represents Microsoft’s ongoing commitment to the success of partners worldwide. The program offers a single, integrated partnering framework that recognizes partner expertise, rewards the total impact that partners have in the technology marketplace, and delivers more value to help partners’ businesses be successful.

Contact Information

Christian Sleight
Chief Technology Officer
Biosign Technologies Inc.
(416) 218-9800 ext. 236
cto@biosign.com

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT[®] medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit www.biosign.com

The CNSX has neither approved nor disapproved the contents of this press release.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES